MA45227A - Peptides pour le traitement de l'ostéoarthrite - Google Patents

Peptides pour le traitement de l'ostéoarthrite

Info

Publication number
MA45227A
MA45227A MA045227A MA45227A MA45227A MA 45227 A MA45227 A MA 45227A MA 045227 A MA045227 A MA 045227A MA 45227 A MA45227 A MA 45227A MA 45227 A MA45227 A MA 45227A
Authority
MA
Morocco
Prior art keywords
osteoarthritis
peptides
treatment
Prior art date
Application number
MA045227A
Other languages
English (en)
Inventor
Claude Carelli
Raffaello Paolini
Christelle Vêtu
Original Assignee
Regulaxis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regulaxis filed Critical Regulaxis
Publication of MA45227A publication Critical patent/MA45227A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA045227A 2016-06-10 2017-06-09 Peptides pour le traitement de l'ostéoarthrite MA45227A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16174056 2016-06-10

Publications (1)

Publication Number Publication Date
MA45227A true MA45227A (fr) 2019-04-17

Family

ID=56132793

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045227A MA45227A (fr) 2016-06-10 2017-06-09 Peptides pour le traitement de l'ostéoarthrite

Country Status (12)

Country Link
US (1) US10813980B2 (fr)
EP (1) EP3468582A1 (fr)
JP (1) JP7010934B2 (fr)
KR (1) KR20190018466A (fr)
CN (1) CN109862905A (fr)
AU (1) AU2017277747A1 (fr)
BR (1) BR112018075613A2 (fr)
CA (1) CA3026984A1 (fr)
IL (1) IL263564B (fr)
MA (1) MA45227A (fr)
RU (1) RU2018145945A (fr)
WO (1) WO2017212057A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108785661A (zh) * 2018-07-20 2018-11-13 深圳市第二人民医院 一种无副作用治疗退行性骨关节病的注射剂及其制备方法
KR20230126458A (ko) 2022-02-23 2023-08-30 중앙대학교 산학협력단 졸참나무 잎 추출물을 유효성분으로 포함하는 골관절염 예방 또는 치료용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1208760B (it) * 1986-11-04 1989-07-10 Ind Farmaceutica Serono S P A Trattamento delle malattie infiammatorie articolari
FR2833012B1 (fr) 2001-12-04 2004-01-30 Centre Nat Rech Scient Peptides agonistes de l'hormone de croissance et leurs applications
US20040127402A1 (en) 2002-12-27 2004-07-01 Vad Vijay B. Injectible composition and method for treating degenerative animal joints
US7803781B2 (en) * 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
US20070184015A1 (en) 2006-02-03 2007-08-09 Soonkap Hahn Novel PEGylation agent
US8975225B2 (en) * 2009-03-19 2015-03-10 Universite Pierre Et Marie Curie (Paris 6) Method for inhibiting growth of chondrocytes in a subject by inhibiting IGF-1
JP5969763B2 (ja) 2009-11-18 2016-08-17 旭化成ファーマ株式会社 ヒト変形性膝関節症の予防剤および／または治療剤および／または増悪抑制剤

Also Published As

Publication number Publication date
JP7010934B2 (ja) 2022-02-10
US10813980B2 (en) 2020-10-27
AU2017277747A1 (en) 2019-01-17
EP3468582A1 (fr) 2019-04-17
WO2017212057A1 (fr) 2017-12-14
CN109862905A (zh) 2019-06-07
US20190298808A1 (en) 2019-10-03
CA3026984A1 (fr) 2017-12-14
IL263564B (en) 2021-07-29
JP2019522046A (ja) 2019-08-08
BR112018075613A2 (pt) 2019-04-09
RU2018145945A (ru) 2020-07-10
KR20190018466A (ko) 2019-02-22
IL263564A (en) 2019-02-03
RU2018145945A3 (fr) 2020-07-10

Similar Documents

Publication Publication Date Title
MA45539A (fr) Dihydropyranopyrimidines pour le traitement d'infections virales
MA49144A (fr) Polythérapies pour le traitement du cancer
MA45036A (fr) Polynucléotides codant pour la citrine pour le traitement de la citrullinémie de type 2
MA47719A (fr) Esketamine pour le traitement de la dépression
MA45192A (fr) Traitement d'association
MA45050A (fr) Polynucléotides codant pour la lipoprotéine lipase destinés au traitement de l'hyperlipidémie
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
MA55629A (fr) Compositions d'anticorps pour le traitement de tumeurs
MA55697A (fr) Molécules d'anticorps pour le traitement du cancer
MA41449A (fr) Polythérapies pour le traitement de cancers
MA45052A (fr) Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille
MA44083A (fr) Composés de biarylmonobactame pour le traitement d'infections bactériennes
MA43746A (fr) Dérivés de 2-cyanoisoindoline pour le traitement du cancer
MA40867A (fr) Méthodes pour le traitement d'infections virales à filoviridae
MA50409A (fr) Polythérapies pour le traitement du cancer
MA48637A (fr) Polythérapies pour le traitement du cancer
MA39748A (fr) Cenicriviroc pour le traitement de la fibrose
MA43000A (fr) Polythérapie pour le traitement de tumeurs malignes
MA54925A (fr) Compositions pour le traitement de troubles acido-basiques
MA42999A (fr) Polythérapie pour le traitement de malignités
MA52252A (fr) Formulation de poudre nasale pour le traitement de l'hypoglycémie
MA43825A (fr) Schémas posologiques pour le traitement d'infections fongiques
MA46086A (fr) Schéma posologique pour le traitement de tumeurs solides
MA44378A (fr) Protéines de fusion immunogènes pour le traitement du cancer
MA43570A (fr) Thérapie génique pour traiter l'hypercholestérolémie familiale